Hemab Therapeutics (NASDAQ:COAG) Reaches New 12-Month High – Here’s What Happened

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG)’s stock price hit a new 52-week high during trading on Monday . The stock traded as high as $37.70 and last traded at $37.13, with a volume of 70017 shares traded. The stock had previously closed at $32.37.

Wall Street Analyst Weigh In

COAG has been the topic of a number of research reports. Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Hemab Therapeutics in a research report on Friday, June 26th. Evercore began coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 price target for the company. Finally, Wedbush assumed coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They set an “outperform” rating and a $42.00 price target for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.40.

Hemab Therapeutics Price Performance

The firm has a 50-day moving average of $27.63.

Hemab Therapeutics (NASDAQ:COAG) last announced its earnings results on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Insider Activity

In related news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were acquired at an average price of $24.98 per share, with a total value of $1,536,844.54. Following the completion of the purchase, the insider directly owned 6,444,637 shares in the company, valued at approximately $160,987,032.26. The trade was a 0.96% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired 2,970,541 shares of company stock valued at $55,459,603 in the last quarter.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.